कंपनी का अवलोकन
Agilon Health, Inc. operates within the Healthcare sector specifically focusing on the Medical Care Facilities industry, delivering essential healthcare services for seniors through primary care physicians across communities in the United States. The firm utilizes a unique business model that manages the total healthcare needs of its patients via a subscription-like per-member per-month arrangement, shifting away from traditional fee-for-service structures. As of the latest data, the company maintains a market capitalization of $329.46M and generates an annual revenue of $5.93B, while employing a workforce of 856 individuals. These valuation and revenue figures indicate that Agilon Health is a mid-sized entity within the broader healthcare infrastructure, possessing a substantial revenue base relative to its market cap which suggests significant operational scale despite current profitability challenges.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $5.93B, yet this figure contrasts sharply with a net income loss of $405,347,008 and an EBITDA loss of $406,182,016, revealing a cost structure where operating expenses and losses significantly outweigh gross revenue generation. This discrepancy between revenue and net income highlights a severe negative impact from the company's operational costs and potential restructuring charges or goodwill impairments common in the transition to new care models. The firm recorded a free cash flow of $-81,226,128, indicating a negative cash position that limits current financial flexibility and necessitates capital raising or operational efficiency improvements to sustain liquidity. Analysis of the three key margins shows a gross margin of -2.7%, an operating margin of -10.0%, and a profit margin of -6.6%, all of which indicate that the company is currently unprofitable at every level of its income statement. In terms of balance sheet strength, the company holds $285.14M in cash against $36.81M in debt, resulting in a debt-to-equity ratio of 29.05, which suggests a capital structure heavily reliant on equity financing rather than debt leverage. The current ratio stands at 1.02, a figure that indicates the company possesses just enough current assets to cover its current liabilities, reflecting a tight short-term liquidity position with minimal buffer. Furthermore, the return on equity is -135.6% and the return on assets is -17.5%, metrics that reveal management has struggled to generate positive returns on the capital invested by shareholders or held on the balance sheet.
मूल्यांकन आकलन
The valuation metrics present a complex picture with a P/E Ratio (TTM) listed as N/A due to negative earnings, while the forward P/E is calculated at -5.42, implying that the market is pricing in significant future earnings recovery or continued losses rather than immediate profitability. The price-to-book ratio of 2.60 suggests that the market values the company at a premium of 160% over its book value, potentially reflecting high expectations for the success of its new care model despite current financials. Alternative valuation measures such as the price-to-sales ratio of 0.06 and the EV/EBITDA of -0.20 indicate that investors are placing a low multiple on the massive revenue base while acknowledging the current lack of earnings power. The stock has experienced extreme volatility, trading within a 52-week range between a low of $7.48 and a high of $152.00, placing the current price significantly below the 52-week high and near the bottom of the established trading band. The beta value of 0.33 indicates that the stock exhibits low price volatility relative to the broader market, moving much less than the overall index and offering a distinct risk profile compared to large-cap peers.
Growth & Income
The company demonstrated a revenue growth rate of 3.1% year-over-year, whereas earnings growth is marked as N/A due to the persistent net losses, implying that top-line expansion has not yet translated into bottom-line profitability. Agilon Health does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company reinvests all available resources into growth initiatives, operational scaling, or debt management rather than returning capital to shareholders. The absence of a dividend yield underscores the firm's current focus on survival and business model transformation rather than income generation for investors seeking passive cash flow. Overall, the growth and income profile is characterized by modest top-line expansion coupled with substantial operating losses and a complete lack of dividend distribution, reflecting a high-risk, high-potential-reward scenario typical of companies in deep restructuring phases.